Treats human immunodeficiency virus type 1 (HIV-1) infection. ANDA 78886, held by Hetero Labs Ltd Iii. Efavirenz.
As of Nov 16, 2026, ANDA 78886 (Efavirenz), held by Hetero Labs Ltd Iii, was first approved by FDA on Apr 27, 2018, with 2 approved supplements and 0 published complete response letters.
Efavirenz tablets in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. Efavirenz is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 27, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Efavirenz600MG · tablet;oral | Efavirenz | Rx |
| Nov 22, 2024 | Supplement 30Labeling · Standard review | Approved | None posted |
| Apr 6, 2023 | Supplement 27Labeling · Standard review | Approved | None posted |
| Apr 27, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters